Concerns about lean mass loss and metabolism Clinical data shows semaglutide can reduce lean body mass, with losses ranging from nearly 0% to 40% of total weight reduction
Despite no information on medical diagnoses, the criterion of prior oral antidiabetic medication use in the pre-index period largely limits the chance of finding off-label use in LRx
Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg vs dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomised controlled trial

Medical Necessity Checklist for Formulary Exception If you're requesting a formulary exception, gather this documentation first: Required Documentation for Exception Request Current BMI documentation (30 or 27 with comorbidity) Documented comorbidities with ICD-10 codes (medical diagnosis codes): Obesity Class I/II/III (E66.811, E66.812, E66.813) Hypertension (I10) Type 2 Diabetes (E11) Dyslipidemia/high cholesterol (E78.5) Obstructive Sleep Apnea (G47.33) Failed alternative treatments documented trials of: Phentermine or diethylpropion Qsymia or Contrave Semaglutide (Wegovy/Ozempic) for 6+ months Lifestyle modification records (diet/exercise program participation) Weight history showing chronic obesity (past 1-2 years) Letter of Medical Necessity from your Kaiser provider For more on prior auth documentation, see our Wegovy prior authorization guide EXCEPTION PATHWAYS How Some Members Get Coverage While standard coverage is limited, some Kaiser members do get Wegovy covered

Although theres no cure, weight loss alone can lead to significant improvement of symptoms and resumption of regular ovulation and menstruation, said Dr